GKB Ophthalmics
- Market cap
- ₹ 34 Cr.
- P/E
- 8.9x
- P/B
- 0.56x
- 52-week range
- 55.01 – 76.02
- ROE
- 3%
- ROCE
- 11%
- Dividend yield
- 0%
- Debt / equity
- 0.22
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE, BSE
About
GKB Ophthalmics Limited is engaged in manufacturing and sale of unfinished ophthalmic lenses. The Company is also focused on the business of manufacturing and supply of semi-finished plastic lenses. The Company operates through the Ophthalmics Lenses segment. Its products consist of organic semifinished lenses, which include single vision, bifocal, progressive and aspheric lenses. The single vision lenses include 1.498 CR-39, 1.50 BLUCHECK, 1.56 CLEAR, 1.56 BLUCHECK, 1.56 DAYNITE, 1.56 DAYNITE FAST CHANGE, 1.50 Q-SHADE+ and 1.50 SUNSENSOR. Its bifocal lenses include 1.498 CR-39, 1.50 BLUCHECK, 1.56 BLUCHECK, 1.56 DAYNITE, 1.56 DAYNITE FAST CHANGE and 1.50 Q-SHADE+. Its progressive lenses include 1.498 CR-39, 1.50 BLUCHECK, 1.56 DAYNITE and 1.56 DAYNITE FAST CHANGE. Its aspheric lens includes 1.498 CR-39. The Company’s products are exported to various countries across the globe. Its subsidiaries include GSV Ophthatmics Private Limited, GKB Ophthalmics Products FZE, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →GKB Ophthalmics against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)8.9 against a typical 26.9: cheaper than most peers (1st = cheapest).3rd of 25
- Sales growth+2.3% against a typical +21.5% from a year earlier.15th of 18
- Size₹ 34.2 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).21st of 24
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated D by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil D | — | 4 Jun 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 4 Jun 2026 | Reaffirmed | Crisil D | — | CRISIL | ₹ 15.1 Cr. | |
| 26 May 2026 | Reaffirmed | Crisil D(Issuer Not Cooperating) → Crisil D | — | CRISIL | ₹ 15.1 Cr. | |
| 23 Dec 2025 | Rating action | Crisil D(Issuer Not Cooperating) | — | CRISIL | ₹ 15.1 Cr. |
Research by Minerva Capital Research Solutions
Our research team's work on GKB OphthalmicsAlso covered in
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 24 | 22 | 26 | 26 | 26 | 31 | 32 | 30 | 57 | 30 | 33 |
| Expenses | 21 | 25 | 22 | 25 | 26 | 27 | 34 | 32 | 27 | 55 | 27 | 30 |
| Operating Profit | −0 | −1 | 0 | 1 | −0 | −1 | −3 | 1 | 3 | 2 | 3 | 3 |
| OPM % | −1.4% | −2.6% | 0% | 4% | −0.2% | −3.6% | −9.2% | 2.5% | 10% | 2.9% | 10.3% | 8% |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | −1 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | −1 | −1 | −1 | 0 | −1 | −2 | −4 | −1 | 2 | 1 | 1 | 2 |
| Tax % | 0% | 0% | 30.4% | 600% | 5.5% | 2.7% | 4.8% | 14.3% | 3.7% | −4.4% | −3.7% | 9.8% |
| Net Profit | −1 | −1 | −1 | 0 | −1 | −2 | −4 | −1 | 2 | 1 | 1 | 2 |
| EPS in Rs | −2.32 | −2.48 | −1.81 | −0.5 | −2.42 | −4.03 | −7.04 | −2.02 | 3.17 | 0.87 | 0.38 | 2 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 21%
- 3 Years
- 25%
- TTM
- 30%
- 10 Years
- 11%
- 5 Years
- 77%
- 3 Years
- 138%
- TTM
- 147%
- 10 Years
- −3%
- 5 Years
- −8%
- 3 Years
- −12%
- TTM
- —
- 10 Years
- −2%
- 5 Years
- −2%
- 3 Years
- −5%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| GKB Ophthalmics | ₹ 60.50 | ₹ 34 Cr. | 8.9x | 0.6x | 3% | — |
| Lenskart Solutions | ₹ 627.55 | ₹ 1,08,959 Cr. | 181x | 10.7x | 6.7% | 5.7% |
| Poly Medicure | ₹ 1,446.80 | ₹ 14,582 Cr. | 52.1x | 5.5x | 11% | 17.1% |
| Laxmi Dental | ₹ 171.25 | ₹ 946 Cr. | 35.6x | 5x | 12.8% | 9.5% |
| One Global Service Provider | ₹ 372.00 | ₹ 721 Cr. | 17x | 8.3x | 65.2% | 14% |
| Mallcom (India) | ₹ 909.00 | ₹ 567 Cr. | 21.9x | 2.1x | 9.7% | 5.6% |
Management
- Krishna Gopal Gupta
- Executive Chairman of the Board, Managing Director
- Noel da Silva
- Chief Financial Officer
Prices are delayed and for information only. Nothing on this page is investment advice.